

Nye legemidler som ikke har markedsføringstillatelse

For legemidler oppført på listen gjelder retningslinjens vilkår uavhengig av indikasjon for bruken.

Oppdatert: 29.01.2026

Virkestoff	Indikasjon per nå. (Samt mulig andre indikasjoner i fremtiden.)	Orphan medicinal product (Se informasjon om COMP (Komiteen for legemidler mot sjeldne sykdommer) på www.legemiddelverket.no	Oppført på listen
abicipar pegol	Treatment of neovascular (wet) age related macular degeneration (AMD)		aug.19
aficamten	Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients		jan.25
allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded	Treatment of graft-versus-host disease.	x	sep.23
allogeneic faecal microbiota, pooled	Treatment of patients with acute-graft-versus-host disease (aGvHD)		jul.25
alpelisib	Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)./ Treatment of patients with severe manifestations of PIK3CArelated overgrowth spectrum - Kun denne indikasjonen	x	jun.25/aug.22
anselamimab	Treatment of adult patients with kappa light chain amyloidosis		des.25
apadamtase alfa	Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency	x	jun.23
apitegromab	Treatment of spinal muscular atrophy		mar.25
arimoclomol	Niemann-Pick disease type C (NPC)	x	des.20
arimoclomol	Treatment of Niemann-Pick disease type C (NPC) in patients aged 6 months and older in combination with miglustat	x	nov.25

artesunate (*Kun styrken 60 mg)	Treatment of severe malaria	x	feb.21
aumolertinib	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer		des.22
autologous human chondrocytes in vitro expanded	Repair of cartilage defects of the knee joint		sep.20
autologous cartilage-derived articular chondrocytes, in-vitro expanded	Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV		jan.24
autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated	Treatment of glioma	x	okt.20
Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein	Treatment of patients with Wiskott-Aldrich Syndrome (WAS)	x	jan.25
autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded	Treatment of melanoma		mai.25
bardoxolone methyl	Treatment of chronic kidney disease (CKD)	x	okt.21 /des.21
belinostat	Relapserad/refraktärt T-cellslymfom		mar.24
belumosudil	Treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy/ Graft versus host disease (GvHD)	x	okt. 24/ nov. 22
bifikafusp alfa /onfekafusp alfa	Neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma		jul.24
blarcamesine	Treatment of Alzheimer's disease and dementia		jan.25
camizestrant	treatment of locally advanced or metastatic breast cancer		jul.25
casimersen	Treatment of duchennes muscular dystrophy		okt.24
catequentinib	Treatment of Ewing sarcoma and soft tissue sarcomas/ Treatment of synovial sarcoma or leiomyosarcoma		jul.25/ aug.25

CNP(89-126) Navepegritide	Treatment of achondroplasia in children		okt.25
copanlisib	Treatment of non-hodgkin lymphoma		mar.18
copanlisib	Treatment of adult patients with marginal zone lymphoma	x	jul.22
daprodustat	Treatment of anemia assicated with chronic kidney disease (CKD) in adults		apr.22
datopotamab	Treatment of adult patients with locally advanced or metastatic non squamous nonsmall cell lung cancer (NSCLC)		apr.24
deferiprone	Treatment of neurodegeneration with brain iron accumulation - Kun denne indikasjonen	x	jun.19
delandistrogene moxeparovovec	Treatment of ambulatory patients aged 3 to 7 years old with Duchenne muscular dystrop. Treatment of Duchenne muscular dystrophy	x	jul.24/aug.23
denecimig	Prophylaxis of bleeding episodes in patients with haemophilia A		okt.25
depatuximab mafodotin	Treatment of glioblastoma (GBM)		nov.18
deuruxolitinib	alopecia areata		jan.26
diazoxide choline	Treatment of adult and paediatric patients with Prader-Willi syndrome	x	jun.25
diclofenamide	Treatment of periodic paralysis		feb.19
donidalorsen	For routine prevention of recurrent attacks of hereditary angioedema (HAE)		jan.25
dorocubicel / allogeneic umbilical cord-derived CD34- cells, non-expanded	Treatment of adult patients with haematological malignancies	x	jul.24
doxecitine / doxribtimine -	Indicated for the treatment of paediatric and adult patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years		des.24
duvelisib	Treatment of adult patients with small lymphocytic lymphoma (SLL) - Kun denne indikasjonen	x	feb.20
edaravone	Amyotrophic lateral sclerosis (ALS)		jan.18
eflornithine / sulindac	Treatment of familial adenomatous polyposis	x	jul.20
eflornithine	Treatment of high-risk neuroblastoma responsive to prior multiagent, multimodality therapy - Kun denne indikasjonen	x	jan.25
emapalumab	acute or recurrent secondary haemophagocytic lymphohistiocytosis (sHLH)		jan.26
enasidenib	Treatment of acute myeloid leukaemia		mar.18

entolimod	Treatment of acute radiation syndrome	x	nov.17
ensartinib	anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).		nov.25
eteplirsen	Treatment of duchennes muscular dystrophy		okt.24
etripamil	Paroxysmal supraventricular tachycardia (PSVT)		nov.25
ferumoxytol	Intravenous treatment of iron deficiency anaemia (IDA)		jun.22
garetsomab	Fibrodysplasia ossificans progressiva (FOP)		jan.26
gefurulimab	Treatment of adult patients with generalised myasthenia gravis (gMG)		des.25
glepaglutide	Treatment of Short Bowel Syndrome		jul.25
glutamine	Treatment of sickle cell disease		mar.18
golodirsen	Treatment of duchennes muscular dystrophy		okt.24
govorestat	Treatment of adults and children aged 2 years and older with a confirmed diagnosis of classic galactosemia	x	jan.24
idebenone	Treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) not using glucocorticoids - Kun denne indikasjonen	x	aug.19
icotrokinra	Treatment of plaque psoriasis in adults and adolescents 12 years or older		nov.25
imlunestrant	Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer		jan.25
infigratinib	Treatment of cholangiocarcinoma	x	des.21
ipatasertib	Treatment of breastcancer		mar.18
lenadogene nolparvovec	Treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)	x	nov.20
lenacapavir	Pre-exposure prophylaxis to prevent HIV-1 (kun denne indikasjonen)		mar.25
leniolisib	Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)	x	nov.22
leriglitazone	Treatment of adrenoleukodystrophy	x	aug.25
lifileucel	Treatment of unresectable or metastatic melanoma		sep.24

linerixibat	Treatment of cholestatic pruritus with primary biliary cholangitis		jul.25
lurbinectedin	Treatment patients with extensive-stage small cell lung cancer (ES-SCLC)		jul.25
LUT014	Topical BRAF Inhibitor Therapy for EGFR Inhibitor-Induced Acneiform Rash		nov.23
mavorixafor	Treatment of WHIM syndrome	x	jan.25
mobocertinib	Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).		jan.21
mozafancogene autotemcel	Treatment of paediatric patients with Fanconi Anaemia Type A	x	mai.24
nadofaragene firadenovec	Treatment of adult patients with high-grade(HG), Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladdercancer (NMIBC),		jan.25
naporafenib	Treatment of advanced solid tumours including ovarian cancer		okt.21
narsoplimab	Treatment in haematopoietic stem cell transplantation, Treatment of patients with haemopoietic stem cell transplant-associated thrombotic microangiopathy.		jul.25/ aug.25
nedosiran	Til behandling av primær hyperoksaluri.		mai.24
nerandomilast	Treatment of idiopathic pulmonary fibrosis. Pulmonary fibrosis		mar.25
nogapendekin alfa / Inbakcept	Treatment of adult patients with BCG-unresponsive non-muscle invasive bladdercancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours		jan.25
norucholic acid	Treatment of primary sclerosing cholangitis (PSC) in adults.	x	aug.25
obeticholic acid	Improvement of liver fibrosis and resolution of steatohepatitis in adult patients with significant liver fibrosis due to nonalcoholic steatohepatitis (NASH). Kun denne indikasjonen		aug.20
obicetrapib	Treatment of primary hypercholesterolaemia or mixed dyslipidaemia		nov.25
obicetrapib / ezetimibe	Treatment of primary hypercholesterolaemia or mixed dyslipidaemia		nov.25

obnitix	Treatment of RR-aGVHD		apr.24
omadacycline tosylate	Treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults		okt.18
omecamtiv mecarbil	Treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%		feb.23
oportuzumab monatox	Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high grade Ta and/or T1 papillary tumours		apr.21
paltusotine	Maintenance treatment in adult patients with acromegaly	x	mar.25
parsaclisib	Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)	x	feb.22
pegcetacoplan	Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) - Kun denne indikasjonen	x	feb.23
pevonedistat	Higher-risk chronic myelomonocytic leukemia (HR-CMML), low-blast acute myeloid leukemia (LB-AML) and higher risk myelodysplastic syndromes		aug.20
pimicotinib	Treatment of tenosynovial giant cell tumour in adults and adolescents from 12 years of age		nov.25
plazomicin	Treatment of symptomatic tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS), where surgical resection is potentially associated with worsening functional limitation or severe morbidity	x	mar.19
plazomicin	Treatment of Complicated urinary tract infection (cUTI), including pyelonephritis; treatment of Bloodstream infection (BSI); treatment of infections due to Enterobacteriaceae		nov.18
plozasiran	Treatment of familial chylomicronemia syndrome		mar.25
povorcitinib	Treatment of active moderate to severe hidradenitis suppurativa (acne inversa)		okt.25

pridopidine	Treatment of Huntington's disease	x	sep.24
relacorilant	Treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer	x	nov.25
remibrutinib	Treatment of chronic spontaneous urticaria. Treatment of chronic inducible urticaria		mar.25
resminostat	Treatment of patients with advanced stage mycosis fungoides (MF) and Sézary syndrome (SS)		apr.24
retifanlimab	Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum (kun denne indikasjonen)	x	mar.21
rilonacept	treatment of idiopathic pericarditis	x	okt.24
rilzabrutinib	Treatment of persistent or chronic immune thrombocytopenia (ITP)	x	des.24
romidepsin	Treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy.		feb.22
rovalpituzumab tesirine	Small cell lung cancer (SCLC)		jan.18
sasanlimab	Indicated for treatment of bladder cancer		jun.25
savolitinib	monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma		mar.23
senaparib	maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer		sep.25
sintilimab	Treatment of non-squamous non-small cell lung cancer in adults		des.25
siponimod	Indicated for the treatment of thrombocytopenia - Kun denne indikasjonen		okt.18
sodium phenylbutyrate/ ursodoxicoltaurine	Treatment of amyotrophic lateral sclerosis (ALS)	x	apr.22
sonotoclax	non-small cell lung cancer		jan.26
surufatinib	Treatment of progressive neuroendocrine tumours		jul.21
tanruprubart	Guillain-Barré syndrome		jan.26
tarlatamab	treatment of small cell lung cancer	x	jul.25
tazemetostat	Treatment of malignant mesothelioma and Epithelioid sarcoma		mai.21
tolebrutinib	Treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adults		mai.25

tovorafenib	Treatment of paediatric low grade glioma		mar.25
trastuzumabduocarmazine	Treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast		aug.22
trilaciclib	prevention of chemotherapy-induced myelosuppression when administered prior to platinum/etoposide- or topotecan-containing regimens for extensive-stage small cell lung cancer (ES SCLC)		sep.25
trofinetide	Treatment of Rett syndrome in adults and paediatric patients 2 years of age and older	x	jan.25
troriluzole	Treatment of adult patients with spinocerebellar ataxia genotype 3 (SCA3)	x	nov.23
valemetostat	Ved tilbakevendende/refraktær (R/R) adult T-cell leukemia/lymphoma (ATLL).		apr.22
veliparib	Treatment of BRCA 1, BRCA 2, BARD1 and/or PALB2 mutated cancer		mar.18
viltolarsen	Treatment of duchennes muscular dystrophy		okt.24
Zopapogene imadenovec	Treatment of respiratory papillomatosis in adults		nov.25